Kyriaki Tzogani
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Beyond maximum grade: key regulatory considerations in adverse event reporting.
Journal: The Lancet. Haematology
Published: March 13, 2026
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series.
Journal: The Lancet. Haematology
Published: January 10, 2025
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.
Journal: The Lancet. Haematology
Published: October 28, 2021
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's Perspective.
Journal: Frontiers in medicine
Published: July 20, 2021
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Journal: The oncologist
Published: December 19, 2019
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Journal: ESMO open
Published: October 02, 2019
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Journal: ESMO open
Published: July 31, 2019
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Journal: The oncologist
Published: July 23, 2019
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Journal: The oncologist
Published: March 28, 2019
Last Updated: 09/26/2026